DC-TAB

N/A

Report date: 2024/10/17 17:05:42

Base Information

Drug NameDC-TAB
Drug Alias NameRecombinant human CRYAB-Delta CrystallonRecombinant human alpha B-crystallin-Delta CrystallonHspB5CRYABSER-101(Serenity Bioworks)
ClassificationBiologics > Protein drugs > Recombinant protein
Mechanisms of ActionImmunomodulatorsCrystallin Alpha B modulators
TargetsAlpha-Crystallin B Chain
Therapy Area/IndicationsMultiple Sclerosis
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBulgariaNetherlands
CombinationsNo
Global Highest StatusPending (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesDelta Crystallon BV
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesSerenity Bioworks IncDelta Crystallon BV
Active IndicationsN/A
Inactive IndicationsMultiple Sclerosis

Other Information

ATC CodeN/A
Related LinksN/A